Clinical Trials Logo

Filter by:
NCT ID: NCT06417502 Recruiting - Autoimmune Diseases Clinical Trials

Observational Study of Pediatric Rheumatic and Immunologic Diseases in China: The CAPRID Registry

Start date: April 29, 2022
Phase:
Study type: Observational [Patient Registry]

An observational, multi-center, longitudinal registry study for Chinese pediatric patients with rheumatic and immunologic diseases.

NCT ID: NCT06417476 Recruiting - Rectal Neoplasms Clinical Trials

Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer

Start date: December 12, 2022
Phase: Phase 2
Study type: Interventional

Given the growing focus on preserving organ function and the utilization of neoadjuvant therapy, it is important to investigate and enhance the application of comprehensive neoadjuvant therapy in low rectal cancer. This approach aims to improve disease-free survival (DFS), while minimizing or circumventing the organ dysfunction and subsequent decline in quality of life associated with radical surgery. Consequently, we propose to initiate a multicenter clinical trial to examine the medium- and long-term effectiveness of complete neoadjuvant therapy (comprising either short-course radiotherapy or long-course chemoradiation, followed by consolidation chemotherapy with mFOLFOXIRI) in increasing organ preservation rates in patients with low rectal cancer.

NCT ID: NCT06417437 Recruiting - Depression Clinical Trials

Non-invasive BCI and Application Verification for Depressed People

Start date: July 1, 2023
Phase: Phase 4
Study type: Interventional

Major Depressive Disorder (MDD) is a serious mental illness and public health problem that poses threat to both physical and mental health. According to statistics from WHO, it is estimated that more than 350 million people worldwide suffer from depression, with a prevalence rate of 2.1% in China, which is approximately 30 million people. At present, due to the lack of neurobiological markers for screening and diagnosing depression, the identification and diagnosis of MDD are based on the judgment of professional doctors, and the treatment mostly relies on clinical symptoms. In terms of treatment, medication remains the main stream for MDD. Although current methods have certain therapeutic effects, patients still suffer from various side effects and poor cognitive function.In current clinical practice, relying purely on symptomatic diagnosis and treatment is difficult to meet the needs of clinical practice, so there is an urgent need to search for neurobiological markers in depression and develop targeted non-invasive intervention technologies. This study aims to combine advanced brain imaging technology, digital twin-brain models, multi-source information decoding technology, integrated detection and intervention technology. The target is to create two new types of non-invasive BCI systems that can regulate emotions. One is a intervention BCI system for MDD that is suitable for hospital settings with the purpose of precise physical stimulation, and the other one is an ecological BCI system that regulate emotions and intervene with depression which is suitable for both hospital settings and future family environments. This study will collect a comprehensive collection of physiological and biochemical indicators from patients with depression and from healthy control groups, as well as multimodal information such as head surface electroencephalography, MRI, and eye movements under different brain states, to personalize the available BCI information of depression related brain regions, circuits, and networks. The study also tries to explore emotional-interactive games that can intervene with depression and build a game data base that is dedicated to MDD. Other goals include designing and establishing two new types of emotional regulation systems, which are precise external physical stimulation intervention and ecological intervention, constructing a BCI regulation system, and conducting application verification to evaluate the regulation effect.

NCT ID: NCT06417424 Recruiting - Clinical trials for Electric Stimulation

Observe Intestinal Tract Cleaness of Senile Constipation Patients Used Gastrointestinal External Stimulation

Start date: February 1, 2024
Phase: N/A
Study type: Interventional

This is a prospective, randomized, double-blind controlled trial. Elderly patients with constipation requiring colonoscopy were randomly divided into four groups: 1. Received both gastrointestinal external stimulation and transcutaneouselectrical acupoint stimulation; 2. Received gastrointestinal external stimulation singly; 3. Received transcutaneouselectrical acupoint stimulation singly; 4. No stimulation was given. All groups received oral administration of polyethylene glycol for intestinal cleansing. Boston Bowel Preparation Scale (BBPS) score was used to assess the quality of intestinal cleanliness , with a total score of 9, and higher scores indicating better intestinal cleanliness, and BBPS≥6 was defined effective.

NCT ID: NCT06417164 Recruiting - Postural Balance Clinical Trials

Effects of FMS Functional Movement Training on Body Posture Control in College Female Aerobics Athletes

Start date: May 25, 2024
Phase: N/A
Study type: Interventional

For this experiment, it was planned to randomly assign 40 female college aerobics athletes to two groups: a traditional physical training group (control group, T, N=20) and a functional training group (experimental group, F, N=20). The control group will use traditional physical training methods, while the experimental group will use a training program based on the FMS functional movement design. The experimental group was scheduled to undergo a 12-week FMS functional movement training intervention, with each session lasting 40 minutes. Before and after the experiment, the subjects' FMS scores, body posture control, and competition performance will be measured.

NCT ID: NCT06417099 Recruiting - Clinical trials for Polycystic Ovary Syndrome

Efficacy of Dihydroartemisinin for Treating PCOS

Start date: May 24, 2024
Phase: Phase 2
Study type: Interventional

The primary research hypothesis of this study is that dihydroartemisinin is effective in restoration of regular menstrual cycles of PCOS subjects who meet at least two of three Rotterdam Criteria. Secondary research hypotheses include: dihydroartemisinin is also effective in reducing androgen, total immature follicles, and anti-Mullerian hormone.

NCT ID: NCT06416709 Recruiting - Lung Injury Clinical Trials

Stem Cell Treatment for Lung Injury Caused by Major Infectious Diseases

Start date: May 10, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this study is to conduct a prospective, double-blind, randomized placebo-controlled clinical trial to investigate the safety and efficacy of mesenchymal stem cells treatment for Lung injury caused by major infectious diseases.

NCT ID: NCT06416696 Recruiting - Cervical Cancers Clinical Trials

Toripalimab for High-risk Locally Advanced Cervical Cancer

Start date: January 9, 2024
Phase: Phase 2
Study type: Interventional

This phase II clinical study assesses the efficacy and safety of Toripalimab combined with chemoradiotherapy (CRT) followed by Toripalimab maintenance in treating high-risk locally advanced cervical cancer (HR-LACC). Despite CRT being the standard treatment, HR-LACC patients face poor survival outcomes. Toripalimab, a cost-effective PD-1 inhibitor, has shown promise in prior research. The primary endpoint is 2-year progression-free survival, with the study aiming to improve treatment accessibility and patient prognoses in China.

NCT ID: NCT06415773 Recruiting - Clinical trials for T2DM (Type 2 Diabetes Mellitus)

Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

Start date: May 2024
Phase: Phase 3
Study type: Interventional

The goal of this clinical study is to evaluate the efficacy and safety of berberine ursodeoxycholate (HTD1801) compared to dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone.

NCT ID: NCT06415708 Recruiting - B Cell Lymphoma Clinical Trials

Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma

Start date: November 30, 2023
Phase: Phase 2
Study type: Interventional

This is a prospective, single-center, single-arm clinical study to evaluate the efficacy and safety of maintenance therapy with obinutuzumab for 2 years in patients ≥ 18 years of age with newly diagnosed mature B-cell lymphoma (including follicular lymphoma[FL], marginal zone cell lymphoma[MZL] , waldenström macroglobulinemia[WM], hairy-cell leukemia variant[HCL-v]) who achieved ≥ PR after 6 cycles of obinutuzumab in combination with bendamustine.